Terms: = Leukemia AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Clinical Outcome
22 results:
1. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract] [Full Text] [Related]
2. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
[TBL] [Abstract] [Full Text] [Related]
3. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV
Burns A; Alsolami R; Becq J; Stamatopoulos B; Timbs A; Bruce D; Robbe P; Vavoulis D; Clifford R; Cabes M; Dreau H; Taylor J; Knight SJL; Mansson R; Bentley D; Beekman R; Martín-Subero JI; Campo E; Houlston RS; Ridout KE; Schuh A
Leukemia; 2018 Feb; 32(2):332-342. PubMed ID: 28584254
[TBL] [Abstract] [Full Text] [Related]
4. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of atm/p53 functional status.
Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
[TBL] [Abstract] [Full Text] [Related]
5. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract] [Full Text] [Related]
6. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.
Shahjahani M; Mohammadiasl J; Noroozi F; Seghatoleslami M; Shahrabi S; Saba F; Saki N
Cell Oncol (Dordr); 2015 Apr; 38(2):93-109. PubMed ID: 25563586
[TBL] [Abstract] [Full Text] [Related]
7. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
[TBL] [Abstract] [Full Text] [Related]
8. Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia.
Mansouri L; Gunnarsson R; Sutton LA; Ameur A; Hooper SD; Mayrhofer M; Juliusson G; Isaksson A; Gyllensten U; Rosenquist R
Am J Hematol; 2012 Jul; 87(7):737-40. PubMed ID: 22674506
[TBL] [Abstract] [Full Text] [Related]
9. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia.
Parker H; Rose-Zerilli MJ; Parker A; Chaplin T; Wade R; Gardiner A; Griffiths M; Collins A; Young BD; Oscier DG; Strefford JC
Leukemia; 2011 Mar; 25(3):489-97. PubMed ID: 21151023
[TBL] [Abstract] [Full Text] [Related]
10. Detection of chromosomal abnormalities associated with chronic lymphocytic leukemia: what is the best method?
El-Taweel M; Barin C; Cymbalista F; Eclache V
Cancer Genet Cytogenet; 2009 Nov; 195(1):37-42. PubMed ID: 19837267
[TBL] [Abstract] [Full Text] [Related]
11. Mutation status of the residual atm allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract] [Full Text] [Related]
12. Bulky lymphadenopathy with poor clinical outcome is associated with atm downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
[TBL] [Abstract] [Full Text] [Related]
13. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia.
Ripollés L; Ortega M; Ortuño F; González A; Losada J; Ojanguren J; Soler JA; Bergua J; Coll MD; Caballín MR
Cancer Genet Cytogenet; 2006 Nov; 171(1):57-64. PubMed ID: 17074592
[TBL] [Abstract] [Full Text] [Related]
14. Relation between genetic variants of the ataxia telangiectasia-mutated (atm) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
Meier M; den Boer ML; Hall AG; Irving JA; Passier M; Minto L; van Wering ER; Janka-Schaub GE; Pieters R
Leukemia; 2005 Nov; 19(11):1887-95. PubMed ID: 16167060
[TBL] [Abstract] [Full Text] [Related]
15. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
Rubio-Moscardo F; Climent J; Siebert R; Piris MA; Martín-Subero JI; Nieländer I; Garcia-Conde J; Dyer MJ; Terol MJ; Pinkel D; Martinez-Climent JA
Blood; 2005 Jun; 105(11):4445-54. PubMed ID: 15718413
[TBL] [Abstract] [Full Text] [Related]
16. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Pettitt AR
Br J Haematol; 2004 Nov; 127(4):425-8. PubMed ID: 15521919
[TBL] [Abstract] [Full Text] [Related]
17. Cryptic deletion involving the atm locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders.
Eclache V; Caulet-Maugendre S; Poirel HA; Djemai M; Robert J; Lejeune F; Raphaël M
Cancer Genet Cytogenet; 2004 Jul; 152(1):72-6. PubMed ID: 15193446
[TBL] [Abstract] [Full Text] [Related]
18. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.
Jones GG; Reaper PM; Pettitt AR; Sherrington PD
Oncogene; 2004 Mar; 23(10):1911-21. PubMed ID: 14755251
[TBL] [Abstract] [Full Text] [Related]
19. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome.
Novitzky N; Davison GM; Hale G; Waldmann H
Transplantation; 2002 Dec; 74(11):1551-9. PubMed ID: 12490788
[TBL] [Abstract] [Full Text] [Related]
20. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
[TBL] [Abstract] [Full Text] [Related]
[Next]
